Clinical relevance of Ephs and ephrins in cancer: Lessons from breast, colorectal, and lung cancer profiling

Seminars in Cell and Developmental Biology

Volumn 23, Issue 1, 2012, Pages 102-108

  Brantley Sieders, Dana M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer; Clinical relevance; Eph; Ephrin; Patient; Profiling

Indexed keywords

EPHRIN; EPHRIN A1; EPHRIN A2; EPHRIN B1; EPHRIN B2; EPHRIN B3; EPHRIN B4; EPHRIN B6; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER GROWTH; COLORECTAL CANCER; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MICROARRAY ANALYSIS; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW;

EID: 84857444267     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2011.10.014     Document Type: Review

References (130)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
2. Hahn W.C., Weinberg R.A. Rules for making human tumor cells. N Engl J Med 2002, 347:1593-1603.
3. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat Med 2004, 10:789-799.
4. Perona R. Cell signalling: growth factors and tyrosine kinase receptors. Clin Transl Oncol 2006, 8:77-82.
5. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365.
6. Wykosky J., Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 2008, 6:1795-1806.
7. Himanen J.P., Saha N., Nikolov D.B. Cell-cell signaling via Eph receptors and ephrins. Curr Opin Cell Biol 2007, 19:534-542.
8. Noren N.K., Pasquale E.B. Paradoxes of the EphB4 receptor in cancer. Cancer Res 2007, 67:3994-3997.
9. Vaught D., Brantley-Sieders D.M., Chen J. Eph receptors in breast cancer: roles in tumor promotion and tumor suppression. Breast Cancer Res 2008, 10:217.
10. Ogawa K., Pasqualini R., Lindberg R.A., Kain R., Freeman A.L., Pasquale E.B. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 2000, 19:6043-6052.
11. Zelinski D.P., Zantek N.D., Stewart J.C., Irizarry A.R., Kinch M.S. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001, 61:2301-2306.
12. Pan M. Overexpression of EphA2 gene in invasive human breast cancer and its association with hormone receptor statues [ASCO annual meeting proceedings]. J Clin Oncol 2005, 23:9583.
13. Fournier M.V., Martin K.J., Kenny P.A., Xhaja K., Bosch I., Yaswen P., et al. Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer. Cancer Res 2006, 66:7095-7102.
14. Martin K.J., Patrick D.R., Bissell M.J., Fournier M.V. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS ONE 2008, 3:e2994.
15. Zhuang G., Brantley-Sieders D.M., Vaught D., Yu J., Xie L., Wells S., et al. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res 2010, 70:299-308.
16. Macrae M., Neve R.M., Rodriguez-Viciana P., Haqq C., Yeh J., Chen C., et al. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 2005, 8:111-118.
17. Brantley-Sieders D.M., Zhuang G., Hicks D., Fang W.B., Hwang Y., Cates J.M., et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 2008, 118:64-78.
18. Larsen A.B., Pedersen M.W., Stockhausen M.T., Grandal M.V., van Deurs B., Poulsen H.S. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol Cancer Res 2007, 5:283-293.
19. Pedersen K., Angelini P.D., Laos S., Bach-Faig A., Cunningham M.P., Ferrer-Ramon C., et al. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol 2009, 29:3319-3331.
20. Brantley-Sieders D.M., Dunaway C.M., Rao M., Short S., Hwang Y., Gao Y., et al. Angiocrine factors modulate tumor proliferation and motility through EphA2 repression of Slit2 tumor suppressor function in endothelium. Cancer Res 2011, 71:976-987.
21. Berclaz G., Andres A.C., Albrecht D., Dreher E., Ziemiecki A., Gusterson B.A., et al. Expression of the receptor protein tyrosine kinase myk-1/htk in normal and malignant mammary epithelium. Biochem Biophys Res Commun 1996, 226:869-875.
22. Wu Q., Suo Z., Risberg B., Karlsson M.G., Villman K., Nesland J.M. Expression of Ephb2 and Ephb4 in breast carcinoma. Pathol Oncol Res 2004, 10:26-33.
23. Berclaz G., Flutsch B., Altermatt H.J., Rohrbach V., Djonov V., Ziemiecki A., et al. Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast. Oncol Rep 2002, 9:985-989.
24. Noren N.K., Foos G., Hauser C.A., Pasquale E.B. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol 2006, 8:815-825.
25. Salvucci O., Maric D., Economopoulou M., Sakakibara S., Merlin S., Follenzi A., et al. EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures. Blood 2009, 114:1707-1716.
26. Fu D.Y., Wang Z.M., Wang B.L., Chen L., Yang W.T., Shen Z.Z., et al. Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer. Hum Pathol 2010, 41:48-58.
27. Fox B.P., Kandpal R.P. Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Commun 2004, 318:882-892.
28. Fox B.P., Tabone C.J., Kandpal R.P. Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines. Biochem Biophys Res Commun 2006, 342:1263-1272.
29. Fox B.P., Kandpal R.P. EphB6 receptor significantly alters invasiveness and other phenotypic characteristics of human breast carcinoma cells. Oncogene 2009, 28:1706-1713.
30. Kandpal R.P. Tyrosine kinase-deficient EphB6 receptor-dependent alterations in proteomic profiles of invasive breast carcinoma cells as determined by difference gel electrophoresis. Cancer Genomics Proteomics 2010, 7:253-260.
31. Truitt L., Freywald T., DeCoteau J., Sharfe N., Freywald A. The EphB6 receptor cooperates with c-Cbl to regulate the behavior of breast cancer cells. Cancer Res 2010, 70:1141-1153.
32. Miao H., Wei B.R., Peehl D.M., Li Q., Alexandrou T., Schelling J.R., et al. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol 2001, 3:527-530.
33. Guo H., Miao H., Gerber L., Singh J., Denning M., Gilliam A.C., et al. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin. Cancer Res 2006, 66:7050-7058.
34. Wykosky J., Palma E., Gibo D.M., Ringler S., Turner C.P., Debinski W. Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene 2008, 27:7260-7273.
35. Alford S., Watson-Hurthig A., Scott N., Carette A., Lorimer H., Bazowski J., et al. Soluble ephrin a1 is necessary for the growth of HeLa and SK-BR3 cells. Cancer Cell Int 2010, 10:41.
36. Stein E., Lane A.A., Cerretti D.P., Schoecklmann H.O., Schroff A.D., Van Etten R.L., et al. Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev 1998, 12:667-678.
37. Alford S.C., Bazowski J., Lorimer H., Elowe S., Howard P.L. Tissue transglutaminase clusters soluble A-type ephrins into functionally active high molecular weight oligomers. Exp Cell Res 2007, 313:4170-4179.
38. Clevers H., Batlle E. EphB/EphrinB receptors and Wnt signaling in colorectal cancer. Cancer Res 2006, 66:2-5.
39. Herath N.I., Boyd A.W. The role of Eph receptors and ephrin ligands in colorectal cancer. Int J Cancer 2010, 126:2003-2011.
40. Stephenson S.A., Slomka S., Douglas E.L., Hewett P.J., Hardingham J.E. Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer. BMC Mol Biol 2001, 2:15.
41. Martiny-Baron G., Korff T., Schaffner F., Esser N., Eggstein S., Marme D., et al. Inhibition of tumor growth and angiogenesis by soluble EphB4. Neoplasia 2004, 6:248-257.
42. Liu W., Ahmad S.A., Jung Y.D., Reinmuth N., Fan F., Bucana C.D., et al. Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer 2002, 94:934-939.
43. Batlle E., Bacani J., Begthel H., Jonkheer S., Gregorieff A., van de Born M., et al. EphB receptor activity suppresses colorectal cancer progression. Nature 2005, 435:1126-1130.
44. Guo D.L., Zhang J., Yuen S.T., Tsui W.Y., Chan A.S., Ho C., et al. Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours. Carcinogenesis 2006, 27:454-464.
45. Chiu S.T., Chang K.J., Ting C.H., Shen H.C., Li H., Hsieh F.J. Over-expression of EphB3 enhances cell-cell contacts and suppresses tumor growth in HT-29 human colon cancer cells. Carcinogenesis 2009, 30:1475-1486.
46. Sheng Z., Wang J., Dong Y., Ma H., Zhou H., Sugimura H., et al. EphB1 is underexpressed in poorly differentiated colorectal cancers. Pathobiology 2008, 75:274-280.
47. Wang J.D., Dong Y.C., Sheng Z., Ma H.H., Li G.L., Wang X.L., et al. Loss of expression of EphB1 protein in gastric carcinoma associated with invasion and metastasis. Oncology 2007, 73:238-245.
48. Jubb A.M., Zhong F., Bheddah S., Grabsch H.I., Frantz G.D., Mueller W., et al. EphB2 is a prognostic factor in colorectal cancer. Clin Cancer Res 2005, 11:5181-5187.
49. Lugli A., Spichtin H., Maurer R., Mirlacher M., Kiefer J., Huusko P., et al. EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers. Clin Cancer Res 2005, 11:6450-6458.
50. Yu G., Gao Y., Ni C., Chen Y., Pan J., Wang X., et al. Reduced expression of EphB2 is significantly associated with nodal metastasis in Chinese patients with gastric cancer. J Cancer Res Clin Oncol 2011, 137:73-80.
51. Davalos V., Dopeso H., Castano J., Wilson A.J., Vilardell F., Romero-Gimenez J., et al. EPHB4 and survival of colorectal cancer patients. Cancer Res 2006, 66:8943-8948.
52. Lloyd J.M., McIver C.M., Stephenson S.A., Hewett P.J., Rieger N., Hardingham J.E. Identification of early-stage colorectal cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells. Clin Cancer Res 2006, 12:417-423.
53. Dong Y., Wang J., Sheng Z., Li G., Ma H., Wang X., et al. Downregulation of EphA1 in colorectal carcinomas correlates with invasion and metastasis. Mod Pathol 2009, 22:151-160.
54. Wang J., Kataoka H., Suzuki M., Sato N., Nakamura R., Tao H., et al. Downregulation of EphA7 by hypermethylation in colorectal cancer. Oncogene 2005, 24:5637-5647.
55. Herath N.I., Doecke J., Spanevello M.D., Leggett B.A., Boyd A.W. Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival. Br J Cancer 2009, 100:1095-1102.
56. Hafner C., Schmitz G., Meyer S., Bataille F., Hau P., Langmann T., et al. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem 2004, 50:490-499.
57. Saito T., Masuda N., Miyazaki T., Kanoh K., Suzuki H., Shimura T., et al. Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis. Oncol Rep 2004, 11:605-611.
58. Yuan W.J., Ge J., Chen Z.K., Wu S.B., Shen H., Yang P., et al. Over-expression of EphA2 and EphrinA-1 in human gastric adenocarcinoma and its prognostic value for postoperative patients. Dig Dis Sci 2009, 54:2410-2417.
59. Yuan W., Chen Z., Wu S., Ge J., Chang S., Wang X., et al. Expression of EphA2 and E-cadherin in gastric cancer: correlated with tumor progression and lymphogenous metastasis. Pathol Oncol Res 2009, 15:473-478.
60. Kataoka H., Igarashi H., Kanamori M., Ihara M., Wang J.D., Wang Y.J., et al. Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci 2004, 95:136-141.
61. Potla L., Boghaert E.R., Armellino D., Frost P., Damle N.K. Reduced expression of EphrinA1 (EFNA1) inhibits three-dimensional growth of HT29 colon carcinoma cells. Cancer Lett 2002, 175:187-195.
62. Li Z., Tanaka M., Kataoka H., Nakamura R., Sanjar R., Shinmura K., et al. EphA2 up-regulation induced by deoxycholic acid in human colon carcinoma cells, an involvement of extracellular signal-regulated kinase and p53-independence. J Cancer Res Clin Oncol 2003, 129:703-708.
63. Bogan C., Chen J., O'Sullivan M.G., Cormier R.T. Loss of EphA2 receptor tyrosine kinase reduces ApcMin/+ tumorigenesis. Int J Cancer 2009, 124:1366-1371.
64. Oshima T., Akaike M., Yoshihara K., Shiozawa M., Yamamoto N., Sato T., et al. Overexpression of EphA4 gene and reduced expression of EphB2 gene correlates with liver metastasis in colorectal cancer. Int J Oncol 2008, 33:573-577.
65. Pasquale E.B. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010, 10:165-180.
66. Kinch M.S., Moore M.B., Harpole D.H. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 2003, 9:613-618.
67. Brannan J.M., Sen B., Saigal B., Prudkin L., Behrens C., Solis L., et al. EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev Res (Phila) 2009, 2:1039-1049.
68. Brannan J.M., Dong W., Prudkin L., Behrens C., Lotan R., Bekele B.N., et al. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res 2009, 15:4423-4430.
69. Choi K., Creighton C.J., Stivers D., Fujimoto N., Kurie J.M. Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations. PLoS ONE 2007, 2:e1226.
70. Faoro L., Singleton P.A., Cervantes G.M., Lennon F.E., Choong N.W., Kanteti R., et al. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem 2010, 285:18575-18585.
71. Davies H., Hunter C., Smith R., Stephens P., Greenman C., Bignell G., et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005, 65:7591-7595.
72. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
73. Alam S.M., Fujimoto J., Jahan I., Sato E., Tamaya T. Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers. Br J Cancer 2008, 98:845-851.
74. Shi G., Yue G., Zhou R. EphA3 functions are regulated by collaborating phosphotyrosine residues. Cell Res 2010, 20:1263-1275.
75. Ji X.D., Li G., Feng Y.X., Zhao J.S., Li J.J., Sun Z.J., et al. EphB3 is overexpressed in non-small-cell lung cancer and promotes tumor metastasis by enhancing cell survival and migration. Cancer Res 2011, 71:1156-1166.
76. Stahl S., Mm Branca R., Efazat G., Ruzzene M., Zhivotovsky B., Lewensohn R., et al. Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor. J Proteome Res 2011, 10:2566-2578.
77. Herath N.I., Spanevello M.D., Sabesan S., Newton T., Cummings M., Duffy S., et al. Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival. BMC Cancer 2006, 6:144.
78. Raza S.M., Fuller G.N., Rhee C.H., Huang S., Hess K., Zhang W., et al. Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis. Clin Cancer Res 2004, 10:212-221.
79. Wang J., Dong Y., Wang X., Ma H., Sheng Z., Li G., et al. Expression of EphA1 in gastric carcinomas is associated with metastasis and survival. Oncol Rep 2010, 24:1577-1584.
80. Kiyokawa E., Takai S., Tanaka M., Iwase T., Suzuki M., Xiang Y.Y., et al. Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in various human tumors. Cancer Res 1994, 54:3645-3650.
81. Giaginis C., Tsourouflis G., Zizi-Serbetzoglou A., Kouraklis G., Chatzopoulou E., Dimakopoulou K., et al. Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma. Pathol Oncol Res 2010, 16:267-276.
82. Maru Y., Hirai H., Yoshida M.C., Takaku F., Evolution, expression, and chromosomal location of a novel receptor tyrosine kinase gene, eph Mol Cell Biol 1988, 8:3770-3776.
83. Chen G., Wang Y., Zhou M., Shi H., Yu Z., Zhu Y., et al. EphA1 receptor silencing by small interfering RNA has antiangiogenic and antitumor efficacy in hepatocellular carcinoma. Oncol Rep 2010, 23:563-570.
84. Fournier M.V., Martin K.J. Transcriptome profiling in clinical breast cancer: from 3D culture models to prognostic signatures. J Cell Physiol 2006, 209:625-630.
85. Lin Y.G., Han L.Y., Kamat A.A., Merritt W.M., Landen C.N., Deavers M.T., et al. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 2007, 109:332-340.
86. Nakamura R., Kataoka H., Sato N., Kanamori M., Ihara M., Igarashi H., et al. EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci 2005, 96:42-47.
87. Xu F., Zhong W., Li J., Shanshen Z., Cui J., Nesland J.M., et al. Predictive value of EphA2 and EphrinA-1 expression in oesophageal squamous cell carcinoma. Anticancer Res 2005, 25:2943-2950.
88. Miyazaki T., Kato H., Fukuchi M., Nakajima M., Kuwano H. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer 2003, 103:657-663.
89. Wykosky J., Gibo D.M., Stanton C., Debinski W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res 2005, 3:541-551.
90. Miao H., Li D.Q., Mukherjee A., Guo H., Petty A., Cutter J., et al. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 2009, 16:9-20.
91. Li X., Wang L., Gu J.W., Li B., Liu W.P., Wang Y.G., et al. Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma. Tumour Biol 2010, 31:477-488.
92. Mudali S.V., Fu B., Lakkur S.S., Luo M., Embuscado E.E., Iacobuzio-Donahue C.A. Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status. Clin Exp Metastasis 2006, 23:357-365.
93. Yang P., Yuan W., He J., Wang J., Yu L., Jin X., et al. Overexpression of EphA2, MMP-9, and MVD-CD34 in hepatocellular carcinoma: Implications for tumor progression and prognosis. Hepatol Res 2009, 39:1169-1177.
94. Walker-Daniels J., Coffman K., Azimi M., Rhim J.S., Bostwick D.G., Snyder P., et al. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 1999, 41:275-280.
95. Abraham S., Knapp D.W., Cheng L., Snyder P.W., Mittal S.K., Bangari D.S., et al. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res 2006, 12:353-360.
96. Wood L.D., Calhoun E.S., Silliman N., Ptak J., Szabo S., Powell S.M., et al. Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers. Hum Mutat 2006, 27:1060-1061.
97. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
98. Bae H.J., Song J.H., Noh J.H., Kim J.K., Jung K.H., Eun J.W., et al. Low frequency mutation of the Ephrin receptor A3 gene in hepatocellular carcinoma. Neoplasma 2009, 56:331-334.
99. Balakrishnan A., Bleeker F.E., Lamba S., Rodolfo M., Daniotti M., Scarpa A., et al. Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res 2007, 67:3545-3550.
100. Fukai J., Yokote H., Yamanaka R., Arao T., Nishio K., Itakura T. EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line. Mol Cancer Ther 2008, 7:2768-2778.
101. Iiizumi M., Hosokawa M., Takehara A., Chung S., Nakamura T., Katagiri T., et al. EphA4 receptor, overexpressed in pancreatic ductal adenocarcinoma, promotes cancer cell growth. Cancer Sci 2006, 97:1211-1216.
102. Wang L.F., Fokas E., Juricko J., You A., Rose F., Pagenstecher A., et al. Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. BMC Cancer 2008, 8:79.
103. Guan M., Xu C., Zhang F., Ye C. Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features. Int J Cancer 2009, 124:88-94.
104. Easty D.J., Hill S.P., Hsu M.Y., Fallowfield M.E., Florenes V.A., Herlyn M., et al. Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 1999, 84:494-501.
105. Feng Y.X., Zhao J.S., Li J.J., Wang T., Cheng S.Q., Yuan Y., et al. Liver cancer: EphrinA2 promotes tumorigenicity through Rac1/Akt/NF-kappaB signaling pathway 120. Hepatology 2010, 51:535-544.
106. Li J.J., Liu D.P., Liu G.T., Xie D. EphrinA5 acts as a tumor suppressor in glioma by negative regulation of epidermal growth factor receptor. Oncogene 2009, 28:1759-1768.
107. Nakada M., Niska J.A., Tran N.L., McDonough W.S., Berens M.E. EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion. Am J Pathol 2005, 167:565-576.
108. Tang X.X., Evans A.E., Zhao H., Cnaan A., Brodeur G.M., Ikegaki N. Association among EPHB2, TrkA, and MYCN expression in low-stage neuroblastomas. Med Pediatr Oncol 2001, 36:80-82.
109. Zhang S., Jiang T., Liang M. Expression of EphB4 and Ephrin B2 in cervical cancer tissues and angiogenesis. Int J Gynaecol Obstet 2007, 96:46-47.
110. Alam S.M., Fujimoto J., Jahan I., Sato E., Tamaya T. Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers. Gynecol Oncol 2009, 114:84-88.
111. Takai N., Miyazaki T., Fujisawa K., Nasu K., Miyakawa I. Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer. Oncol Rep 2001, 8:567-573.
112. Berclaz G., Karamitopoulou E., Mazzucchelli L., Rohrbach V., Dreher E., Ziemiecki A., et al. Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma. Ann Oncol 2003, 14:220-226.
113. Lee Y.C., Perren J.R., Douglas E.L., Raynor M.P., Bartley M.A., Bardy P.G., et al. Investigation of the expression of the EphB4 receptor tyrosine kinase in prostate carcinoma. BMC Cancer 2005, 5:119.
114. Jin M., Komohara Y., Shichijo S., Harada M., Yamanaka R., Miyamoto S., et al. Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients. Oncol Rep 2008, 19:1277-1283.
115. Jin M., Komohara Y., Shichijo S., Yamanaka R., Nikawa J., Itoh K., et al. Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ glioma patients. Cancer Sci 2008, 99:1656-1662.
116. Tang X.X., Evans A.E., Zhao H., Cnaan A., London W., Cohn S.L., et al. High-level expression of EPHB6, EFNB2, and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastomas. Clin Cancer Res 1999, 5:1491-1496.
117. Tang X.X., Zhao H., Robinson M.E., Cohen B., Cnaan A., London W., et al. Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma. Proc Natl Acad Sci USA 2000, 97:10936-10941.
118. Tang X.X., Zhao H., Robinson M.E., Cnaan A., London W., Cohn S.L., et al. Prognostic significance of EPHB6, EFNB2, and EFNB3 expressions in neuroblastoma. Med Pediatr Oncol 2000, 35:656-658.
119. Hafner C., Bataille F., Meyer S., Becker B., Roesch A., Landthaler M., et al. Loss of EphB6 expression in metastatic melanoma. Int J Oncol 2003, 23:1553-1559.
120. Castellvi J., Garcia A., de la Torre J., Hernandez J., Gil A., Xercavins J., et al. Ephrin B expression in epithelial ovarian neoplasms correlates with tumor differentiation and angiogenesis. Hum Pathol 2006, 37:883-889.
121. Nakada M., Anderson E.M., Demuth T., Nakada S., Reavie L.B., Drake K.L., et al. The phosphorylation of ephrin-B2 ligand promotes glioma cell migration and invasion. Int J Cancer 2010, 126:1155-1165.
122. Sawai Y., Tamura S., Fukui K., Ito N., Imanaka K., Saeki A., et al. Expression of ephrin-B1 in hepatocellular carcinoma: possible involvement in neovascularization. J Hepatol 2003, 39:991-996.
123. Tachibana M., Tonomoto Y., Hyakudomi R., Hyakudomi M., Hattori S., Ueda S., et al. Expression and prognostic significance of EFNB2 and EphB4 genes in patients with oesophageal squamous cell carcinoma. Dig Liver Dis 2007, 39:725-732.
124. Vogt T., Stolz W., Welsh J., Jung B., Kerbel R.S., Kobayashi H., et al. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas. Clin Cancer Res 1998, 4:791-797.
125. Hoelzinger D.B., Mariani L., Weis J., Woyke T., Berens T.J., McDonough W.S., et al. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 2005, 7:7-16.
126. Nakada M., Drake K.L., Nakada S., Niska J.A., Berens M.E. Ephrin-B3 ligand promotes glioma invasion through activation of Rac1. Cancer Res 2006, 66:8492-8500.
127. Brantley-Sieders D.M., Jiang A., Sarma K., Badu-Nkansah A., Walter D.L., Shyr Y., Chen J. Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. PLoS One 2011, 6:e24426.
128. Zhuang G, Wong W, Amato K, Hwang Y, Lee K, Boothby M, Ye F, Guo Y, Shyr Y, Lin L, Carbone D, Brantley-Sieders D, Chen J. Cancer-associated EphA3 mutations attenuate tumor-suppressive effects of normal EphA3 in lung cancer. JNCI. (in revision).
129. Brantley-Sieders D.M., Chen J. Eph receptor tyrosine kinases in angiogenesis: from development to disease. Angiogenesis 2004, 7:17-28.
130. Pasquale E.B. Eph receptors and ephrins in cancer: bidirectional signaling and beyond. Nat Rev Cancer 2010, 10:165-180.